AR039352A1 - Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5. - Google Patents
Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5.Info
- Publication number
- AR039352A1 AR039352A1 ARP020101765A ARP020101765A AR039352A1 AR 039352 A1 AR039352 A1 AR 039352A1 AR P020101765 A ARP020101765 A AR P020101765A AR P020101765 A ARP020101765 A AR P020101765A AR 039352 A1 AR039352 A1 AR 039352A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- seq
- compound
- inhibitors
- igs5
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Uso de un compuesto que tiene actividad inhibidora combinada y en particular concurrente de endopeptidasa neutra (NEP) y una novedosa metaloproteasa denominada IGS5, que es un polipéptido que comprende una secuencia de aminoácidos que tiene una identidad de al menos 70% con relación a una de las secuencias de aminoácidos elegidas del grupo de SEQ ID NO: 2, SEQ ID NO: 4 y SEQ ID NO: 6; o una sal o solvato o éster biolábil farmacéuticamente aceptable del mismo, para la preparación de un medicamento o composición farmacéutica para tratar mamíferos superiores y preferiblemente seres humanos que sufren de o son susceptibles a una enfermedad o condición que puede ser aliviada o impedida por inhibición combinada o concurrente de IGS5. Además la presente se refiere a una composición farmacéutica que comprende cantidades co-eficaces y preferiblemente sinérgicamente eficaces de un primer compuesto que tiene actividad inhibidora combinada o concurrente de NEP/IGS5, preferiblemente derivados de ácido benzazepin-n-acético sustituido de la fórmula (1) o una sal, solvato o éster biolábil farmacéuticamente aceptable del mismo, y al menos un compuesto adicional elegido del grupo de otros inhibidores de metalopoteasa individuales y/o combinantes, estando elegido preferiblemente dicho compuesto del grupo que comprende los inhibidores de ACE, inhibidores selectivos de ECE, inhibidores selectivos de NEP, inhibidores duales de NEP/ECE, inhibidores mixtos de estas metaloproteasas. Reivindicación 10: Uso de un compuesto de la fórmula (1), en la cual: A representa un grupo con las fórmulas (2) o (3), en cuya fórmula (2) R1a representa un grupo fenil-(alquilo inferior), opcionalmente sustituido en el ciclo fenilo por alquilo inferior, alcoxi inferior o halógeno o un grupo naftil-(alquilo inferior), R2a representan hidrógeno o un grupo que forma un éster biolábil y en cuya fórmula (3) R1b representa hidrógeno o un grupo que forma un éster de ácido fosfónico biolábil, R2b es hidrógeno o un grupo que forma un éster de ácido fosfónico biolábil, y en donde R3 representa hidrógeno o un grupo que forma un éster de ácido carboxílico biolábil, o una sal o solvato o éster biolábil farmacéuticamente aceptable del mismo para la preparación de un medicamento o composición farmacéutica para tratar mamíferos superiores, preferiblemente seres humanos, que sufren de o son susceptibles a una enfermedad o condición que puede ser aliviada o impedida por inhibición combinada o concurrente de: a) endopeptidasa neutra (NEP) y b) metaloproteasa IGS5 que es un polipéptido que comprende una secuencia de aminoácidos que tiene una identidad de a menos 70% con relación a una de las secuencias de aminoácidos elegida del grupo que comprende SEQ ID NO: 2, SEQ ID NO: 4, y SEQ ID NO: 6.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01112231 | 2001-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR039352A1 true AR039352A1 (es) | 2005-02-16 |
Family
ID=32842671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020101765A AR039352A1 (es) | 2001-05-18 | 2002-05-14 | Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20040162345A1 (es) |
EP (1) | EP1397141A2 (es) |
JP (1) | JP2004536063A (es) |
CN (1) | CN1520299A (es) |
AR (1) | AR039352A1 (es) |
BR (1) | BR0209855A (es) |
CA (1) | CA2447598A1 (es) |
CZ (1) | CZ20033183A3 (es) |
HU (1) | HUP0400988A3 (es) |
MX (1) | MXPA03010341A (es) |
PL (1) | PL367093A1 (es) |
RU (1) | RU2003136077A (es) |
SK (1) | SK14102003A3 (es) |
WO (1) | WO2002094176A2 (es) |
ZA (1) | ZA200308098B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1234025B1 (en) | 1999-11-19 | 2008-08-27 | Solvay Pharmaceuticals B.V. | Human enzymes of the metalloprotease family |
US7927791B2 (en) * | 2002-07-24 | 2011-04-19 | Ptc Therapeutics, Inc. | Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mRNA decay |
US7452875B2 (en) | 2003-09-26 | 2008-11-18 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
US7262184B2 (en) | 2003-09-26 | 2007-08-28 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
US7427611B2 (en) | 2003-09-26 | 2008-09-23 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
US7232813B2 (en) | 2004-01-12 | 2007-06-19 | Solvay Pharmaceuticals B.V. | Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders |
JP4951350B2 (ja) * | 2004-01-12 | 2012-06-13 | アボツト・ヘルスケア・プロダクツ・ベー・ブイ | 神経変性障害の予防及び処置のための中性エンドペプチダーゼ(nep)及びヒト可溶性エンドペプチダーゼ(hsep)阻害剤 |
US20050267124A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors |
US20050267072A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction |
EP1753432A1 (en) * | 2004-05-14 | 2007-02-21 | Solvay Pharmaceuticals GmbH | Medicaments containing dually acting inhibitors of neutral endopeptidase and of human soluble endopeptidase for the treatment of sexual dysfunction |
US20050288272A1 (en) * | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
RU2384346C2 (ru) * | 2004-06-23 | 2010-03-20 | Зольвай Фармасьютиклз Гмбх | Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора |
MX2007006279A (es) * | 2004-12-15 | 2007-06-14 | Solvay Pharm Gmbh | Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa. |
US20060205625A1 (en) * | 2005-02-18 | 2006-09-14 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
JP2008530182A (ja) * | 2005-02-18 | 2008-08-07 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Nep阻害剤、内因性エンドセリン産生系の阻害剤及び利尿剤を含有する薬剤学的組成物 |
KR101970505B1 (ko) | 2012-12-26 | 2019-04-19 | (주)아모레퍼시픽 | 멜라닌 형성 억제제를 함유하는 미백용 피부 외용제 조성물 |
MX2017010528A (es) | 2015-02-16 | 2018-11-12 | Univ Queensland | Sulfonilureas y compuestos relacionados y uso de estos. |
TWI752907B (zh) * | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
JP7235742B2 (ja) | 2017-07-07 | 2023-03-08 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
JP2020531453A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | Nlrp3阻害剤としてのスルホニルウレアおよびスルホニルチオウレア |
US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
EP3668861A1 (en) * | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
SG11202003984UA (en) | 2017-11-09 | 2020-05-28 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
PL424452A1 (pl) * | 2018-01-31 | 2019-08-12 | Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu |
WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR880007441A (ko) * | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
ATE158816T1 (de) * | 1990-11-26 | 1997-10-15 | Genetics Inst | Expression von pace in wirtszellen und verfahren zu dessen verwendung |
DE19510566A1 (de) * | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
DE19750002A1 (de) * | 1997-11-12 | 1999-05-20 | Solvay Pharm Gmbh | Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
US20020086405A1 (en) * | 2000-09-25 | 2002-07-04 | Inmaculada Silos-Santiago | 56638, a novel human neprilysin protease and uses thereof |
DE19906310A1 (de) * | 1999-02-16 | 2000-08-17 | Solvay Pharm Gmbh | Arzneimittel zur Behandlung von Bluthochdruck |
DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
JP2001275687A (ja) * | 2000-04-04 | 2001-10-09 | Masafumi Matsuo | 膜結合型メタロプロテアーゼ及びその可溶性分泌型 |
GB0017387D0 (en) * | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
US6991916B2 (en) * | 2000-07-14 | 2006-01-31 | Pfizer Inc. | Compounds for the treatment of sexual dysfunction |
US20030119714A1 (en) * | 2000-12-15 | 2003-06-26 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
-
2002
- 2002-05-14 RU RU2003136077/15A patent/RU2003136077A/ru not_active Application Discontinuation
- 2002-05-14 MX MXPA03010341A patent/MXPA03010341A/es not_active Application Discontinuation
- 2002-05-14 AR ARP020101765A patent/AR039352A1/es not_active Application Discontinuation
- 2002-05-14 CN CNA028101545A patent/CN1520299A/zh active Pending
- 2002-05-14 WO PCT/EP2002/005259 patent/WO2002094176A2/en not_active Application Discontinuation
- 2002-05-14 JP JP2002590897A patent/JP2004536063A/ja not_active Withdrawn
- 2002-05-14 EP EP02743004A patent/EP1397141A2/en not_active Withdrawn
- 2002-05-14 CA CA002447598A patent/CA2447598A1/en not_active Abandoned
- 2002-05-14 BR BR0209855-5A patent/BR0209855A/pt not_active IP Right Cessation
- 2002-05-14 PL PL02367093A patent/PL367093A1/xx not_active Application Discontinuation
- 2002-05-14 CZ CZ20033183A patent/CZ20033183A3/cs unknown
- 2002-05-14 HU HU0400988A patent/HUP0400988A3/hu unknown
- 2002-05-14 SK SK1410-2003A patent/SK14102003A3/sk unknown
-
2003
- 2003-10-17 ZA ZA200308098A patent/ZA200308098B/en unknown
- 2003-11-18 US US10/715,112 patent/US20040162345A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002094176A3 (en) | 2003-12-11 |
JP2004536063A (ja) | 2004-12-02 |
CA2447598A1 (en) | 2002-11-28 |
CN1520299A (zh) | 2004-08-11 |
SK14102003A3 (sk) | 2004-08-03 |
MXPA03010341A (es) | 2004-03-10 |
ZA200308098B (en) | 2004-10-18 |
EP1397141A2 (en) | 2004-03-17 |
HUP0400988A3 (en) | 2006-07-28 |
HUP0400988A2 (hu) | 2004-08-30 |
WO2002094176A2 (en) | 2002-11-28 |
RU2003136077A (ru) | 2005-08-10 |
PL367093A1 (en) | 2005-02-21 |
CZ20033183A3 (cs) | 2004-07-14 |
US20040162345A1 (en) | 2004-08-19 |
BR0209855A (pt) | 2004-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR039352A1 (es) | Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5. | |
DE60217114D1 (de) | Verbrückte bizyklische serinproteaseinhibitoren | |
ATE539744T1 (de) | Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem | |
DK1615613T3 (da) | Quinoxalinyl-makrocykliske hepatitis C serin protease-inhibitorer | |
WO2006039488A3 (en) | Hcv ns3-ns4a protease inhibition | |
UY37998A (es) | Agentes antivirales contra la hepatitis b | |
MY148123A (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
WO2008106058A3 (en) | Inhibitors of serine proteases | |
UY30437A1 (es) | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c | |
HK1101402A1 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
AR036101A1 (es) | Derivados naftil indol sustituidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento como inhibidores del inhibidor de tipo -1 activador de plasminogeno (pai-1) | |
MX2010006210A (es) | Inhibidores de serina proteasa de hcv de tripeptido fluorado. | |
UY30392A1 (es) | Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c | |
WO2003087092A3 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease | |
WO2008021956A3 (en) | Acylaminoheteroaryl hepatitis c virus protease inhibitors | |
UY28423A1 (es) | Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.- | |
EA200100971A1 (ru) | Новые соединения и композиции в качестве ингибиторов протеазы | |
MY155851A (en) | Quinoxaline-containing compounds as hepatitis c virus inhibitors | |
NO20062101L (no) | Serinproteaseinhibitorer, spesielt hcv ns3-ns4a-protease | |
AR027533A1 (es) | Derivados de acido malonico, procesos para su preparacion, su uso y composiciones farmaceuticas que los contienen | |
EA200700976A1 (ru) | Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой | |
RS52945B (en) | PHARMACEUTICAL FORMULATIONS AND THEIR APPLICATION IN THE TREATMENT OF WOMEN SEXUAL DYSFUNCTION | |
PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
AR054550A1 (es) | Metodos para tratar la epileptogenesis | |
EA200301203A1 (ru) | Новые соединения и композиции как ингибиторы катепсина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |